Cristina Caffara writes for the OECD Session on “Rethinking Antitrust tools in Multisided Markets”.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...